EPS for Arena Pharmaceuticals, Inc. (ARNA) Expected At $-0.72

October 13, 2018 - By Hugh Holland

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Logo

Analysts expect Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) to report $-0.72 EPS on November, 6.They anticipate $0.07 EPS change or 10.77 % from last quarter’s $-0.65 EPS. After having $-0.65 EPS previously, Arena Pharmaceuticals, Inc.’s analysts see 10.77 % EPS growth. The stock increased 0.68% or $0.27 during the last trading session, reaching $39.88. About 242,097 shares traded. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has risen 66.28% since October 13, 2017 and is uptrending. It has outperformed by 50.66% the S&P500.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Ratings Coverage

Among 2 analysts covering Arena Pharma (NASDAQ:ARNA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Arena Pharma had 3 analyst reports since April 18, 2018 according to SRatingsIntel. The stock has “Outperform” rating by Credit Suisse on Tuesday, August 7. The stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has “Buy” rating given on Wednesday, May 9 by Cantor Fitzgerald. The stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has “Buy” rating given on Wednesday, April 18 by Cantor Fitzgerald.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The company has market cap of $1.97 billion. The company's proprietary investigational clinical programs include etrasimod , which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It currently has negative earnings. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH.

More notable recent Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: Affimed’s Cancer Drug Placed On Clinical Hold, Celgene’s Positive Scalp Psoriasis Trial” on October 09, 2018, also Streetinsider.com with their article: “After-Hours Stock Movers 09/24: (ASNA) (PSTI) (ARNA) Higher; (SNDX) (OPNT) (CTL) Lower (more…)” published on September 24, 2018, Seekingalpha.com published: “Arena Pharma up 3% after hours on positive olorinab data” on September 24, 2018. More interesting news about Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) were released by: Seekingalpha.com and their article: “Arena Pharma’s ralinepag shows durable treatment effect in mid-stage PAH extension study; shares up 1% premarket” published on October 02, 2018 as well as Seekingalpha.com‘s news article titled: “Is Arena Pharmaceuticals’ Market Capitalization Justified?” with publication date: October 05, 2018.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>